Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 2
1951 2
1952 3
1954 1
1956 1
1958 1
1961 1
1963 1
1964 1
1966 1
1968 1
1978 1
1979 2
1980 2
1981 1
1983 1
1986 1
1991 1
1993 1
1994 1
1995 2
1997 4
1998 1
1999 2
2000 1
2001 1
2002 1
2003 4
2005 1
2006 1
2007 6
2008 4
2009 5
2010 5
2011 4
2012 4
2014 4
2015 3
2016 10
2017 5
2018 6
2019 9
2020 4
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

108 results
Results by year
Filters applied: . Clear all
Page 1
Pembrolizumab for Early Triple-Negative Breast Cancer.
Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J; KEYNOTE-522 Investigators. Schmid P, et al. Among authors: mcarthur h. N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549. N Engl J Med. 2020. PMID: 32101663 Clinical Trial.
The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice.
Gonzalez-Ericsson PI, Stovgaard ES, Sua LF, Reisenbichler E, Kos Z, Carter JM, Michiels S, Le Quesne J, Nielsen TO, Laenkholm AV, Fox SB, Adam J, Bartlett JM, Rimm DL, Quinn C, Peeters D, Dieci MV, Vincent-Salomon A, Cree I, Hida AI, Balko JM, Haynes HR, Frahm I, Acosta-Haab G, Balancin M, Bellolio E, Yang W, Kirtani P, Sugie T, Ehinger A, Castaneda CA, Kok M, McArthur H, Siziopikou K, Badve S, Fineberg S, Gown A, Viale G, Schnitt SJ, Pruneri G, Penault-Llorca F, Hewitt S, Thompson EA, Allison KH, Symmans WF, Bellizzi AM, Brogi E, Moore DA, Larsimont D, Dillon DA, Lazar A, Lien H, Goetz MP, Broeckx G, El Bairi K, Harbeck N, Cimino-Mathews A, Sotiriou C, Adams S, Liu SW, Loibl S, Chen IC, Lakhani SR, Juco JW, Denkert C, Blackley EF, Demaria S, Leon-Ferre R, Gluz O, Zardavas D, Emancipator K, Ely S, Loi S, Salgado R, Sanders M; International Immuno-Oncology Biomarker Working Group. Gonzalez-Ericsson PI, et al. Among authors: mcarthur h. J Pathol. 2020 Apr;250(5):667-684. doi: 10.1002/path.5406. Epub 2020 Apr 9. J Pathol. 2020. PMID: 32129476 Free article. Review.
Current Landscape of Immunotherapy in Breast Cancer: A Review.
Adams S, Gatti-Mays ME, Kalinsky K, Korde LA, Sharon E, Amiri-Kordestani L, Bear H, McArthur HL, Frank E, Perlmutter J, Page DB, Vincent B, Hayes JF, Gulley JL, Litton JK, Hortobagyi GN, Chia S, Krop I, White J, Sparano J, Disis ML, Mittendorf EA. Adams S, et al. Among authors: mcarthur hl. JAMA Oncol. 2019 Aug 1;5(8):1205-1214. doi: 10.1001/jamaoncol.2018.7147. JAMA Oncol. 2019. PMID: 30973611
If we build it they will come: targeting the immune response to breast cancer.
Gatti-Mays ME, Balko JM, Gameiro SR, Bear HD, Prabhakaran S, Fukui J, Disis ML, Nanda R, Gulley JL, Kalinsky K, Abdul Sater H, Sparano JA, Cescon D, Page DB, McArthur H, Adams S, Mittendorf EA. Gatti-Mays ME, et al. Among authors: mcarthur h. NPJ Breast Cancer. 2019 Oct 29;5:37. doi: 10.1038/s41523-019-0133-7. eCollection 2019. NPJ Breast Cancer. 2019. PMID: 31700993 Free PMC article. Review.
A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer.
Ho AY, Barker CA, Arnold BB, Powell SN, Hu ZI, Gucalp A, Lebron-Zapata L, Wen HY, Kallman C, D'Agnolo A, Zhang Z, Flynn J, Dunn SA, McArthur HL. Ho AY, et al. Among authors: mcarthur hl. Cancer. 2020 Feb 15;126(4):850-860. doi: 10.1002/cncr.32599. Epub 2019 Nov 20. Cancer. 2020. PMID: 31747077 Free article. Clinical Trial.
Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy.
Page DB, Yuan J, Redmond D, Wen YH, Durack JC, Emerson R, Solomon S, Dong Z, Wong P, Comstock C, Diab A, Sung J, Maybody M, Morris E, Brogi E, Morrow M, Sacchini V, Elemento O, Robins H, Patil S, Allison JP, Wolchok JD, Hudis C, Norton L, McArthur HL. Page DB, et al. Among authors: mcarthur hl. Cancer Immunol Res. 2016 Oct;4(10):835-844. doi: 10.1158/2326-6066.CIR-16-0013. Epub 2016 Sep 1. Cancer Immunol Res. 2016. PMID: 27587469 Free PMC article. Clinical Trial.
Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study.
Autio KA, Klebanoff CA, Schaer D, Kauh JSW, Slovin SF, Adamow M, Blinder VS, Brahmachary M, Carlsen M, Comen E, Danila DC, Doman TN, Durack JC, Fox JJ, Gluskin JS, Hoffman DM, Kang S, Kang P, Landa J, McAndrew PF, Modi S, Morris MJ, Novosiadly R, Rathkopf DE, Sanford R, Chapman SC, Tate CM, Yu D, Wong P, McArthur HL. Autio KA, et al. Among authors: mcarthur hl. Clin Cancer Res. 2020 Nov 1;26(21):5609-5620. doi: 10.1158/1078-0432.CCR-20-0855. Epub 2020 Aug 26. Clin Cancer Res. 2020. PMID: 32847933
Immunotherapy in Breast Cancer: the New Frontier.
Hu ZI, McArthur HL. Hu ZI, et al. Among authors: mcarthur hl. Curr Breast Cancer Rep. 2018;10(2):35-40. doi: 10.1007/s12609-018-0274-y. Epub 2018 Apr 16. Curr Breast Cancer Rep. 2018. PMID: 29881518 Free PMC article. Review.
Optimizing (neo)adjuvant treatment of HER2-positive breast cancer.
Basho RK, McArthur HL. Basho RK, et al. Among authors: mcarthur hl. Ther Adv Med Oncol. 2018 Jun 24;10:1758835918775697. doi: 10.1177/1758835918775697. eCollection 2018. Ther Adv Med Oncol. 2018. PMID: 30034547 Free PMC article. Review.
108 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page